Thomas Bols serves as Senior Vice President and Managing Director for DIA Europe, Middle East, and Africa (EMEA). Thomas Bols joined DIA after a distinguished career in the biopharmaceutical industry, having held consulting and corporate international public affairs positions at Amgen, Merck KGaA, and Biogen. While working at the intersection of market access, government affairs, public affairs, health policy, corporate communications, and patient advocacy, he spearheaded initiatives that were pivotal to bringing much-needed medicines to patients.
Throughout his career, Mr. Bols has advised and represented companies and industry federations in interactions with policy makers, patient representatives, media, regulators, payers, and other national and European health policy stakeholders. He was responsible for delivering strategic objectives and tactical results that contributed to commercial success and health policy advancements at both the national and European level.
Mr. Bols held board positions at several European associations, including Europabio and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), and chaired a variety of working groups related to regulatory and access issues within the European Federation of Pharmaceutical Industries and Associations (EFPIA). He was also a member of the European Commission High Level Pharmaceutical Forum (2005-2008) and its Process on Corporate Responsibility in the Field of Pharmaceuticals (2010-2012).
Mr. Bols earned a post-graduate degree in European law from the University of Amsterdam.
Our Leadership
-
PharmD •Chair DIA
Senior Advisor R&D
Bayer AG -
MBA •Immediate Past Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
RPh •Chair-Elect DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd. -
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
MS • Global Chief Executive
DIA
-
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
MD •Director DIA
Chief Scientific Officer
Syneos Health -
CPA •Director DIA
Partner, Life Science Industry Practice Group, RSM US -
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
PhD •Director DIA
Senior Vice President
QIAGEN -
MD, PhD •Director DIA
Vice President and Senior Managing Director, Development & Medical Affairs, GlaxoSmithKline Japan -
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
PharmD •Director DIA
President, R&D Design and Delivery Innovation, IQVIA
-
PharmD • Chair, Executive Committee
-
CPA • Member, Executive Committee -
MBA • Member, Executive Committee -
RPh • Member, Executive Committee -
MS • Member, Executive Committee
-
CPA • Chair, Audit Committee -
MD, PhD, DSc • Member, Audit Committee -
MPharm • Member, Audit Committee -
PharmD • Member, Audit Committee -
PharmD • Member, Audit Committee
-
PhD • Chair, Council of Regulators
Leadership Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board -
PhD • Council of Regulators
Leadership Committee
European Medicines Agency Liaison to the DIA Board -
MD • Council of Regulators
Leadership Committee
US Food and Drug Administration Liaison to the DIA Board -
PhD • Council of Regulators
Swissmedic Liaison to the DIA Board
-
MS • Global Chief Executive -
MS, CPA • Chief Financial Officer -
-
DIA EMEA -
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
PhD • Senior Vice President & Managing Director
DIA Americas -
PhD • Senior Vice President & Managing Director
DIA Japan -
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China